AprilBio Issues 150 Billion Won in Third-Party Allotment for Management Transfer, Diluting Shares by 15% but Gaining Strategic Partner TKG Huchems
AprilBio has signed a management change contract with TKG Huchems on June 24, 2026, issuing 3,492,189 convertible preferred shares at 42,953 won per share to raise a total of 150 billion won.
The new share issuance results in a 14.9% dilution of existing shares, partially offset by a 25% premium to the current market price, reducing downward pressure on the stock.
The new shares are subject to a one-year lock-up, and the new board will consist of three TKG-nominated directors and two major shareholder-nominated directors, ensuring stable governance.
TKG Huchems, the acquirer, is a financially sound company with total assets of 1.168 trillion won, equity of 908.3 billion won, and net profit of 59.2 billion won, expected to bring synergy with its chemical business.
[AI Summary]AprilBio's 150 billion won third-party allotment for management transfer to TKG Huchems causes a 14.9% dilution but secures a strategic investor at a premium, providing long-term growth potential. Shareholders should weigh short-term dilution against improved financial stability and corporate value.